Results were that incidence of biliary disease, i.e., conditions that effect the gallbladder/bile ducts, (per 1,000 person-years) was 11.7 for semaglutide, 18.6 for liraglutide (another GLP-1 agonist), and 12.6 for bupropion-naltrexone and 4.6, 7.9 and 1.0, respectively, for pancreatitis
Both Wegovy and Mounjaro are GLP-1 agonists but differ in their specific mechanisms and targets within the body GLP-1 (glucagon-like peptide-1) agonists are a class of medications designed to mimic the effects of the natural hormone GLP-1
Collectively, these findings indicate that carefully engineered CQDs offer low in vitro toxicity while offering broad functional potential in biomedical research and applications
Hassani B, Goshtasbi G, Nooraddini S et al
Pricing for compounded semaglutide starts at $129 for the first month and $189 for each month after